Project description
Online networking to bridge nuclear MRI with rare disease treatment
According to statistics, rare diseases affect 36 million people in the EU with 75 % of patients being children and 30 % dying under the age of five. The majority of the known 8 000 rare diseases lack approved treatments, and the EU has provided financial incentives for pharmaceutical companies to develop effective orphan drugs. The EU-funded RD-MRI NETWORK project represents an effort to find the solution which bridges the gap between pharma, academia and hospitals by providing an online network that combines expert clinical sites, full trial design, the most advanced MRI methodologies and smart automated MRI data processing and coordination. As many potential partners experience significant limitations such as a lack of modern MRI imaging, this project will be fundamental in bringing technology to full market potential, involving the 150 000 clinical sites and 36 million rare disease patients in the EU.
Objective
Rare diseases affect 36 million citizens in the EU with 75% of patients being children and 30% dying under the age of five. 94% of the 8,000 rare diseases lack approved treatments and the EU has created financial incentives for pharmaceutical companies (PhC) to develop suitable orphan drugs but they face difficulties through increasingly high development risks where a failed drug trial can cost €1.8bn on average. In order to lower their costs, PhCs outsource development work to Contractual Research Organizations (CRO) who specialise in specific task such as drug discovery or clinical trials but these CROs have significant limitations such as a lack of modern Nuclear Magnetic Resonance Imaging (MRI) methodologies, EMA/FDA compliance, contacts to clinical sites and restricted access to rare disease patient groups. We present MRI NETWORK, the first solution which bridges the gap between PhCs and clinical sites by providing an online network of expert clinical sites, full trial design, the most advanced MRI methodologies and smart automated MRI data processing & coordination. This project will be fundamental in bringing our technology to full market readiness and reach the 150,000 clinical sites and 36 million rare disease patients in the EU. Our company, CRIS, has been involved in 30+ clinical trials in the past 20 years and with our extensive commercial network of clinical sites, academic experts, pharmaceutical companies and the relevant regulatory institutions, we expect to generate €15.4m in profits with an ROI of 6.7 over 3 years. RD-MRI NETWORK creates a new market for clinical trials and MRI services in the EU and, next to 17 direct jobs, we will create 500+ new skilled jobs by allowing academics to receive adequate compensation for MRI services and increase industry collaborations in academia.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- engineering and technology medical engineering diagnostic imaging magnetic resonance imaging
- natural sciences computer and information sciences data science data processing
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
7503 TOURNAI
Belgium
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.